Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia
Background Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking. Methods We conducted a nested case–control study where we assayed 4...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2018-10, Vol.63 (10), p.2765-2772 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2772 |
|---|---|
| container_issue | 10 |
| container_start_page | 2765 |
| container_title | Digestive diseases and sciences |
| container_volume | 63 |
| creator | Varga, Matthew G. Cai, Hui Waterboer, Tim Murphy, Gwen Shimazu, Taichi Taylor, Phil R. Qiao, You-Lin Park, Sue K. Yoo, Keun-Young Jee, Sun Ha Cho, Eo Rin Kim, Jeongseon Abnet, Christian C. Tsugane, Shoichiro Cai, Qiuyin Zheng, Wei Pawlita, Michael Shu, Xiao-Ou Epplein, Meira |
| description | Background
Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.
Methods
We conducted a nested case–control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein–Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.
Results
The prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78–1.17), EBNA (OR 0.88, 95% CI 0.72–1.08), EA (OR 0.97, 95% CI 0.79–1.19), and ZEBRA (OR 0.87, 95% CI 0.71–1.07) were not associated with risk of incident gastric cancer. When we stratified these data by
H. pylori
status, there was no change in the association.
Conclusions
Multiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations. |
| doi_str_mv | 10.1007/s10620-018-5154-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6139270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712937469</galeid><sourcerecordid>A712937469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-16c37b6f5cf41dd6d8f13070081de5da5c801f571222548787f59426048b7eae3</originalsourceid><addsrcrecordid>eNp1kt9uFCEUxonR2G31AbwxJN54M5XD8G9uTNbNWk0aTUz1zhCWYbbUWViB0fSu7-Ab-iSy2dpao-ECOPy-Dw75EHoC5BgIkS8yEEFJQ0A1HDhruntoBly2DeVC3UczAqKuAcQBOsz5ghDSSRAP0QHtOqY472bo83Kbi_Ph59WPVyYl_MmnKeN5KH4V-0t85otLdZ8cfhcLnuccrTfF9fi7L-f4xOSSvMULE6xL-IPPX7APeFnLlfXmEXowmDG7x9fzEfr4enm2eNOcvj95u5ifNpa3sjQgbCtXYuB2YND3olcDtEQSoqB3vDfcKgIDl0Ap5UxJJQfeMSoIUyvpjGuP0Mu973ZabVxvXSjJjHqb_MakSx2N13dPgj_X6_hNC2g7Kkk1eH5tkOLXyeWiNz5bN44muDhlTYkgSjIFbUWf_YVexCmF2l6leH0fYy2_pdZmdNqHIdZ77c5Uz2sfXSuZ6Cp1_A-qjt5tvI3BDb7W7whgL7Ap5pzccNMjEL3LhN5nQtdM6F0m9E7z9M_PuVH8DkEF6B7I9SisXbrt6P-uvwCMfL_0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2052544435</pqid></control><display><type>article</type><title>Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia</title><source>SpringerLink Journals - AutoHoldings</source><creator>Varga, Matthew G. ; Cai, Hui ; Waterboer, Tim ; Murphy, Gwen ; Shimazu, Taichi ; Taylor, Phil R. ; Qiao, You-Lin ; Park, Sue K. ; Yoo, Keun-Young ; Jee, Sun Ha ; Cho, Eo Rin ; Kim, Jeongseon ; Abnet, Christian C. ; Tsugane, Shoichiro ; Cai, Qiuyin ; Zheng, Wei ; Pawlita, Michael ; Shu, Xiao-Ou ; Epplein, Meira</creator><creatorcontrib>Varga, Matthew G. ; Cai, Hui ; Waterboer, Tim ; Murphy, Gwen ; Shimazu, Taichi ; Taylor, Phil R. ; Qiao, You-Lin ; Park, Sue K. ; Yoo, Keun-Young ; Jee, Sun Ha ; Cho, Eo Rin ; Kim, Jeongseon ; Abnet, Christian C. ; Tsugane, Shoichiro ; Cai, Qiuyin ; Zheng, Wei ; Pawlita, Michael ; Shu, Xiao-Ou ; Epplein, Meira</creatorcontrib><description>Background
Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.
Methods
We conducted a nested case–control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein–Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.
Results
The prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78–1.17), EBNA (OR 0.88, 95% CI 0.72–1.08), EA (OR 0.97, 95% CI 0.79–1.19), and ZEBRA (OR 0.87, 95% CI 0.71–1.07) were not associated with risk of incident gastric cancer. When we stratified these data by
H. pylori
status, there was no change in the association.
Conclusions
Multiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-018-5154-9</identifier><identifier>PMID: 29948559</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies ; Antigens ; Biochemistry ; Cancer ; Epstein-Barr virus ; Gastric cancer ; Gastroenterology ; Health aspects ; Health risk assessment ; Hepatology ; Medicine ; Medicine & Public Health ; Oncology ; Oncology, Experimental ; Original Article ; Risk factors ; Stomach cancer ; Transplant Surgery ; Viral antibodies</subject><ispartof>Digestive diseases and sciences, 2018-10, Vol.63 (10), p.2765-2772</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-16c37b6f5cf41dd6d8f13070081de5da5c801f571222548787f59426048b7eae3</citedby><cites>FETCH-LOGICAL-c537t-16c37b6f5cf41dd6d8f13070081de5da5c801f571222548787f59426048b7eae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-018-5154-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-018-5154-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29948559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varga, Matthew G.</creatorcontrib><creatorcontrib>Cai, Hui</creatorcontrib><creatorcontrib>Waterboer, Tim</creatorcontrib><creatorcontrib>Murphy, Gwen</creatorcontrib><creatorcontrib>Shimazu, Taichi</creatorcontrib><creatorcontrib>Taylor, Phil R.</creatorcontrib><creatorcontrib>Qiao, You-Lin</creatorcontrib><creatorcontrib>Park, Sue K.</creatorcontrib><creatorcontrib>Yoo, Keun-Young</creatorcontrib><creatorcontrib>Jee, Sun Ha</creatorcontrib><creatorcontrib>Cho, Eo Rin</creatorcontrib><creatorcontrib>Kim, Jeongseon</creatorcontrib><creatorcontrib>Abnet, Christian C.</creatorcontrib><creatorcontrib>Tsugane, Shoichiro</creatorcontrib><creatorcontrib>Cai, Qiuyin</creatorcontrib><creatorcontrib>Zheng, Wei</creatorcontrib><creatorcontrib>Pawlita, Michael</creatorcontrib><creatorcontrib>Shu, Xiao-Ou</creatorcontrib><creatorcontrib>Epplein, Meira</creatorcontrib><title>Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.
Methods
We conducted a nested case–control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein–Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.
Results
The prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78–1.17), EBNA (OR 0.88, 95% CI 0.72–1.08), EA (OR 0.97, 95% CI 0.79–1.19), and ZEBRA (OR 0.87, 95% CI 0.71–1.07) were not associated with risk of incident gastric cancer. When we stratified these data by
H. pylori
status, there was no change in the association.
Conclusions
Multiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Biochemistry</subject><subject>Cancer</subject><subject>Epstein-Barr virus</subject><subject>Gastric cancer</subject><subject>Gastroenterology</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Hepatology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Article</subject><subject>Risk factors</subject><subject>Stomach cancer</subject><subject>Transplant Surgery</subject><subject>Viral antibodies</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kt9uFCEUxonR2G31AbwxJN54M5XD8G9uTNbNWk0aTUz1zhCWYbbUWViB0fSu7-Ab-iSy2dpao-ECOPy-Dw75EHoC5BgIkS8yEEFJQ0A1HDhruntoBly2DeVC3UczAqKuAcQBOsz5ghDSSRAP0QHtOqY472bo83Kbi_Ph59WPVyYl_MmnKeN5KH4V-0t85otLdZ8cfhcLnuccrTfF9fi7L-f4xOSSvMULE6xL-IPPX7APeFnLlfXmEXowmDG7x9fzEfr4enm2eNOcvj95u5ifNpa3sjQgbCtXYuB2YND3olcDtEQSoqB3vDfcKgIDl0Ap5UxJJQfeMSoIUyvpjGuP0Mu973ZabVxvXSjJjHqb_MakSx2N13dPgj_X6_hNC2g7Kkk1eH5tkOLXyeWiNz5bN44muDhlTYkgSjIFbUWf_YVexCmF2l6leH0fYy2_pdZmdNqHIdZ77c5Uz2sfXSuZ6Cp1_A-qjt5tvI3BDb7W7whgL7Ap5pzccNMjEL3LhN5nQtdM6F0m9E7z9M_PuVH8DkEF6B7I9SisXbrt6P-uvwCMfL_0</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Varga, Matthew G.</creator><creator>Cai, Hui</creator><creator>Waterboer, Tim</creator><creator>Murphy, Gwen</creator><creator>Shimazu, Taichi</creator><creator>Taylor, Phil R.</creator><creator>Qiao, You-Lin</creator><creator>Park, Sue K.</creator><creator>Yoo, Keun-Young</creator><creator>Jee, Sun Ha</creator><creator>Cho, Eo Rin</creator><creator>Kim, Jeongseon</creator><creator>Abnet, Christian C.</creator><creator>Tsugane, Shoichiro</creator><creator>Cai, Qiuyin</creator><creator>Zheng, Wei</creator><creator>Pawlita, Michael</creator><creator>Shu, Xiao-Ou</creator><creator>Epplein, Meira</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181001</creationdate><title>Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia</title><author>Varga, Matthew G. ; Cai, Hui ; Waterboer, Tim ; Murphy, Gwen ; Shimazu, Taichi ; Taylor, Phil R. ; Qiao, You-Lin ; Park, Sue K. ; Yoo, Keun-Young ; Jee, Sun Ha ; Cho, Eo Rin ; Kim, Jeongseon ; Abnet, Christian C. ; Tsugane, Shoichiro ; Cai, Qiuyin ; Zheng, Wei ; Pawlita, Michael ; Shu, Xiao-Ou ; Epplein, Meira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-16c37b6f5cf41dd6d8f13070081de5da5c801f571222548787f59426048b7eae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Biochemistry</topic><topic>Cancer</topic><topic>Epstein-Barr virus</topic><topic>Gastric cancer</topic><topic>Gastroenterology</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Hepatology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Article</topic><topic>Risk factors</topic><topic>Stomach cancer</topic><topic>Transplant Surgery</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varga, Matthew G.</creatorcontrib><creatorcontrib>Cai, Hui</creatorcontrib><creatorcontrib>Waterboer, Tim</creatorcontrib><creatorcontrib>Murphy, Gwen</creatorcontrib><creatorcontrib>Shimazu, Taichi</creatorcontrib><creatorcontrib>Taylor, Phil R.</creatorcontrib><creatorcontrib>Qiao, You-Lin</creatorcontrib><creatorcontrib>Park, Sue K.</creatorcontrib><creatorcontrib>Yoo, Keun-Young</creatorcontrib><creatorcontrib>Jee, Sun Ha</creatorcontrib><creatorcontrib>Cho, Eo Rin</creatorcontrib><creatorcontrib>Kim, Jeongseon</creatorcontrib><creatorcontrib>Abnet, Christian C.</creatorcontrib><creatorcontrib>Tsugane, Shoichiro</creatorcontrib><creatorcontrib>Cai, Qiuyin</creatorcontrib><creatorcontrib>Zheng, Wei</creatorcontrib><creatorcontrib>Pawlita, Michael</creatorcontrib><creatorcontrib>Shu, Xiao-Ou</creatorcontrib><creatorcontrib>Epplein, Meira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varga, Matthew G.</au><au>Cai, Hui</au><au>Waterboer, Tim</au><au>Murphy, Gwen</au><au>Shimazu, Taichi</au><au>Taylor, Phil R.</au><au>Qiao, You-Lin</au><au>Park, Sue K.</au><au>Yoo, Keun-Young</au><au>Jee, Sun Ha</au><au>Cho, Eo Rin</au><au>Kim, Jeongseon</au><au>Abnet, Christian C.</au><au>Tsugane, Shoichiro</au><au>Cai, Qiuyin</au><au>Zheng, Wei</au><au>Pawlita, Michael</au><au>Shu, Xiao-Ou</au><au>Epplein, Meira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>63</volume><issue>10</issue><spage>2765</spage><epage>2772</epage><pages>2765-2772</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background
Epstein–Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.
Methods
We conducted a nested case–control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein–Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.
Results
The prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78–1.17), EBNA (OR 0.88, 95% CI 0.72–1.08), EA (OR 0.97, 95% CI 0.79–1.19), and ZEBRA (OR 0.87, 95% CI 0.71–1.07) were not associated with risk of incident gastric cancer. When we stratified these data by
H. pylori
status, there was no change in the association.
Conclusions
Multiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29948559</pmid><doi>10.1007/s10620-018-5154-9</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2018-10, Vol.63 (10), p.2765-2772 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6139270 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Antibodies Antigens Biochemistry Cancer Epstein-Barr virus Gastric cancer Gastroenterology Health aspects Health risk assessment Hepatology Medicine Medicine & Public Health Oncology Oncology, Experimental Original Article Risk factors Stomach cancer Transplant Surgery Viral antibodies |
| title | Epstein–Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A04%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epstein%E2%80%93Barr%20Virus%20Antibody%20Titers%20Are%20Not%20Associated%20with%20Gastric%20Cancer%20Risk%20in%20East%20Asia&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Varga,%20Matthew%20G.&rft.date=2018-10-01&rft.volume=63&rft.issue=10&rft.spage=2765&rft.epage=2772&rft.pages=2765-2772&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-018-5154-9&rft_dat=%3Cgale_pubme%3EA712937469%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2052544435&rft_id=info:pmid/29948559&rft_galeid=A712937469&rfr_iscdi=true |